Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.

Protein chemical formula

Not Available

Protein average weight

Not Available

Sequences

Not Available

Synonyms

Not Available

External IDs

Amg 386

Categories

UNII

X8Y5U6NC7E

CAS number

894356-79-7

Pharmacology

Indication: Not Available
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
Alendronic acid	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Alendronic acid.
Clodronic acid	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Clodronic acid.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trebananib.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trebananib.
Etidronic acid	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Etidronic acid.
Ibandronate	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Ibandronate.
Incadronic acid	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Incadronic acid.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trebananib.
Pamidronic acid	The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Pamidronic acid.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Trebananib.

Additional Data Available

Extended Description

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

References

General References

Not Available

External Links

PubChem Substance: 347911276

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Active Not Recruiting	Treatment	Advanced Solid Tumors	1
1	Completed	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia	1
1	Completed	Treatment	Adult Solid Neoplasm / Lung Carcinoid Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Uterine Corpus Sarcoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IV Renal Cell Cancer / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma	1
1	Completed	Treatment	Advanced Solid Tumors	2
1	Completed	Treatment	Advanced Solid Tumors / Impaired kidney function / Kidney Diseases	1
1	Completed	Treatment	Breast Cancer / Locally Recurrent and Metastatic Breast Cancer / Malignancies / Metastases / Metastatic Cancers / Neoplasms, Breast / Oncology / Tumors / Tumors, Breast / Tumors, Solid	1
1	Completed	Treatment	Carcinoma NOS / Fallopian Tube Cancer / Gynecological Malignancies / Malignancies / Metastases / Oncology / Ovarian Cancer / Tumors / Tumors, Solid	1
1	Completed	Treatment	Carcinoma NOS / Fallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer	1
1	Completed	Treatment	Central Nervous System Neoplasms / Solid Neoplasms	1
1	Completed	Treatment	Neoplasms, Advanced Solid	1
1	Completed	Treatment	Tumors	1
1, 2	Completed	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
2	Active Not Recruiting	Treatment	Advanced Renal Cell Carcinoma / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer AJCC V7	1
2	Active Not Recruiting	Treatment	Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Oligodendrogliomas / Recurrent Brain Neoplasm / Recurrent Glioblastoma	1
2	Completed	Treatment	Adult Angiosarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma	1
2	Completed	Treatment	Advanced Hepatocellular Carcinoma / Inoperable Hepatocellular Carcinoma	1
2	Completed	Treatment	Advanced Renal Cell Carcinoma	2
2	Completed	Treatment	Carcinoma NOS / Colorectal Cancers / Gastrointestinal Cancers / Malignancies / Malignant Neoplasm of Colon / Metastases / Metastatic Cancers / Metastatic Colorectal Cancer (MCRC) / Oncology / Rectal Carcinoma	1
2	Completed	Treatment	Endometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Endometrioid Stromal Sarcoma / Recurrent Uterine Corpus Carcinoma	1
2	Completed	Treatment	Fallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer	1
2	Completed	Treatment	Gastrointestinal Cancers	1
2	Completed	Treatment	Locally Recurrent and Metastatic Breast Cancer	1
2	Completed	Treatment	Neoplasms of the Prostate / Prostate Cancer / Prostate Neoplasms / Prostatic Neoplams / Prostatic Neoplasms	1
2	Recruiting	Treatment	Breast Cancer / Hemangiosarcoma / Neoplasms, Breast / Tumors, Breast	1
2	Unknown Status	Treatment	Metastatic Colorectal Cancer (MCRC)	1
2	Withdrawn	Treatment	Transitional Cell Carcinoma	1
3	Completed	Treatment	Fallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer	1
3	Terminated	Treatment	Fallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Cancer	1
3	Terminated	Treatment	Fallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer	1

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State: Not Available
Experimental Properties: Not Available

Taxonomy

Description: Not Available
Kingdom: Organic Compounds
Super Class: Organic Acids
Class: Carboxylic Acids and Derivatives
Sub Class: Amino Acids, Peptides, and Analogues
Direct Parent: Peptides
Alternative Parents: Not Available
Substituents: Not Available
Molecular Framework: Not Available
External Descriptors: Not Available

Drug created on October 20, 2016 15:16 / Updated on March 01, 2020 21:05